drugset / Trial / NCT04529226
Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis
RandomizedParallel-groupOpen-labelTreatment
Summary
This clinical trial will prove whether a large number of people with intellectual disability and treatment-resistant psychosis could benefit from the use of clozapine. Benefit will mean a measurable significant improvement in subjects' clinical response and quality of life.
Timeline
- Start
- 2020-11-26
- Primary completion
- 2025-01-30
- Completion
- 2025-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clozapine | Other / unclassified | 300 mg | Oral |
| Subject | Clozapine | Other / unclassified | 450 mg | Oral |
| Comparator | Amisulpride | Small molecule | — | — |
| Comparator | Haloperidol | Other / unclassified | — | — |
| Comparator | Olanzapine | Small molecule | — | — |
| Comparator | Pimozide | Small molecule | — | — |
| Comparator | Risperidone | Other / unclassified | — | — |